Stay updated with breaking news from Chris hassig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled. ....